Showing 1682 results
-
Press release /New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
-
Story /More than 100,000 patients with heart failure in China are using our new AI-enabled platform, AI Nurse, to manage their condition and aim for better health.
-
Story /Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.
-
Press release /New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
-
Press release /China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is…
-
Press release /- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated…
-
Story /A new type of medicine that targets RNA was discovered by accident and could change the way some diseases are treated.
-
Press release /Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…